XML 46 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Segment Information
 12 Months Ended
Jun. 30, 2021
Segment Reporting [Abstract]  
Segment Reporting Disclosure [Text Block] SEGMENT AND GEOGRAPHIC INFORMATIONAs discussed in Note 1, Basis of Presentation and Summary of Significant Accounting Policies, the Company conducts its business within the following segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Company evaluates the performance of its segments based on segment revenue and segment earnings before non-controlling interest, other (income) expense, impairments, restructuring costs, interest expense, income tax (benefit) expense, and depreciation and amortization (“Segment EBITDA”). The Company considers its reporting segments results in the context of a similar Company-wide measure: EBITDA from operations, which the Company defines as consolidated earnings from operations before interest expense, income tax (benefit) expense, depreciation and amortization, adjusted for the income or loss attributable to non-controlling interest. Neither Segment EBITDA nor EBITDA from operations is defined under U.S.
GAAP, and neither is a measure of operating income, operating performance, or liquidity presented in accordance with U.S. GAAP. Each of these non-GAAP measures is subject to important limitations. These consolidated financial statements include information concerning Segment EBITDA and EBITDA from operations (a) because Segment EBITDA and EBITDA from operations are operational measures used by management in the assessment of the operating segments, the allocation of resources to the segments, and the setting of strategic goals and annual goals for the segments, and (b) in order to provide supplemental information that the Company considers relevant for the readers of the consolidated financial statements, but such information is not meant to replace or supersede U.S. GAAP measures. The Company’s presentation of Segment EBITDA and EBITDA from operations may not be comparable to similarly titled measures used by other companies. The most directly comparable U.S. GAAP measure to EBITDA from operations is net earnings. Included in this Note is a reconciliation of net earnings to EBITDA from operations.
The following tables include net revenue and Segment EBITDA for each of the Company's current reporting segments during the fiscal years ended June 30, 2021, 2020, and 2019:
(Dollars in millions)Fiscal Year Ended June 30,
202120202019
Net revenue:
Biologics$1,928 $1,021 $573 
Softgel and Oral Technologies1,012 1,062 1,039 
Oral and Specialty Delivery686 676 598 
Clinical Supply Services391 345 322 
Inter-segment revenue elimination(19)(10)(14)
Net revenue$3,998 $3,094 $2,518 
(Dollars in millions)Fiscal Year Ended June 30,
202120202019
Segment EBITDA reconciled to net earnings:
Biologics$608 $237 $147 
Softgel and Oral Technologies237 257 236 
Oral and Specialty Delivery160 201 175 
Clinical Supply Services108 91 85 
Subtotal$1,113 $786 $643 
Reconciling items to net earnings
Unallocated costs (1)
1 (146)(143)
Depreciation and amortization(289)(254)(229)
Interest expense, net(110)(126)(111)
Income tax expense(130)(39)(23)
Net earnings$585 $221 $137 
(1)    Unallocated costs include restructuring and special items, stock-based compensation, gain (loss) on sale of subsidiary, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows:
(Dollars in millions)Fiscal Year Ended June 30,
202120202019
Impairment charges and gain (loss) on sale of assets$(9)$(5)$(5)
Stock-based compensation(51)(48)(33)
Restructuring and other special items (a)
(31)(42)(58)
Gain (loss) on sale of subsidiary (b)
182 (1)— 
Other expense, net (c)
(3)(8)(3)
Non-allocated corporate costs, net(87)(42)(44)
Total unallocated costs$1 $(146)$(143)
(a) Restructuring and other special items for the fiscal year ended June 30, 2021 include transaction and integration costs associated with the Anagni, MaSTherCell, Skeletal, Delphi, and Acorda acquisitions, and restructuring costs associated with the closure of the Company's Clinical Supply Services facility in Bolton, U.K.
Restructuring and other special items during the fiscal year ended June 30, 2020 include transaction and integration costs associated with the Company’s cell and gene therapy acquisitions and the disposal of a facility in Australia.
Restructuring and other special items during fiscal 2019 include transaction and integration costs associated with the acquisitions of Paragon Bioservices, Inc. and Juniper Pharmaceuticals, Inc., and the disposal of a facility in Australia.
(b) Gain on sale of subsidiary for the fiscal year ended June 30, 2021 is affiliated with the sale of the Blow-Fill-Seal Business. Loss on sale of subsidiary for the fiscal year ended June 30, 2020 is affiliated with the disposal of the Australia facility.
(c) Refer to Note 15, Other expense, net, for details of financing charges and foreign currency translation adjustments recorded within other expense, net.
The following table includes total assets for each segment, as well as reconciling items necessary to total the amounts reported in the consolidated balance sheets.
Total Assets
(Dollars in millions)June 30, 2021June 30, 2020
Biologics$4,973 $3,775 
Softgel and Oral Technologies1,604 1,502 
Oral and Specialty Delivery1,269 1,248 
Clinical Supply Services483 451 
Corporate and eliminations783 801 
Total assets$9,112 $7,777 
Capital Expenditures
Fiscal Year Ended June 30,
(Dollars in millions)202120202019
Biologics$516 $330 $79 
Softgel and Oral Technologies61 54 83 
Oral and Specialty Delivery64 55 29 
Clinical Supply Services26 10 3 
Corporate19 17 24 
Total capital expenditures$686 $466 $218 
The following table presents long-lived assets(1) by geographic area:  
Long-Lived Assets (1)
(Dollars in millions)June 30, 2021June 30, 2020
United States$1,867 $1,396 
Europe541 405 
Other116 100 
Total$2,524 $1,901 
(1)     Long-lived assets include property, plant, and equipment, net of accumulated depreciation.
 [1]
[1] Refer to Note 15, Other expense, net, for details of financing charges and foreign currency translation adjustments recorded within other expense, net.